These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Bensch F; van der Veen EL; Lub-de Hooge MN; Jorritsma-Smit A; Boellaard R; Kok IC; Oosting SF; Schröder CP; Hiltermann TJN; van der Wekken AJ; Groen HJM; Kwee TC; Elias SG; Gietema JA; Bohorquez SS; de Crespigny A; Williams SP; Mancao C; Brouwers AH; Fine BM; de Vries EGE Nat Med; 2018 Dec; 24(12):1852-1858. PubMed ID: 30478423 [TBL] [Abstract][Full Text] [Related]
11. In Vivo Evaluation and Dosimetry Estimate for a High Affinity Affibody PET Tracer Targeting PD-L1. Rubins DJ; Meng X; McQuade P; Klimas M; Getty K; Lin SA; Connolly BM; O'Malley SS; Haley H; Purcell M; Gantert L; Holahan M; Lindgren J; Eklund P; Ekblad C; Frejd FY; Hostetler ED; González Trotter DE; Evelhoch JL Mol Imaging Biol; 2021 Apr; 23(2):241-249. PubMed ID: 33098025 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of Chelator-to-Antibody Ratio on Development of Tsai SC; Farn SS; Lo WL; Ou Yang FY; Kang YC; Chen LC; Chen KT; Liao JW; Kung JY; Chen JT; Huang FJ Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38138961 [No Abstract] [Full Text] [Related]
14. Non-invasive immunoPET imaging of PD-L1 using anti-PD-L1-B11 in breast cancer and melanoma tumor model. Bansal A; Pandey MK; Barham W; Liu X; Harrington SM; Lucien F; Dong H; Park SS; DeGrado TR Nucl Med Biol; 2021; 100-101():4-11. PubMed ID: 34119742 [TBL] [Abstract][Full Text] [Related]